Abstract:The COVID-19 pandemic represents a global challenge that has impacted and is expected to continue to impact the lives and health of people across the world for the foreseeable future. The rollout of vaccines has provided highly anticipated relief, but effective therapeutics are required to further reduce the risk and severity of infections. Monoclonal antibodies have been shown to be effective as therapeutics for SARS-CoV-2, but as new variants of concern (VoC) continue to emerge, their utility and use have waned due to limited or no efficacy against these variants. Furthermore, cumbersome systemic administration limits easy and broad access to such drugs. As well, concentrations of systemically administered antibodies in the mucosal epithelium, a primary site of initial infection, are dependent on neonatal Fc receptor mediated transport and require high drug concentrations. To reduce the viral load more effectively in the lung, we developed an inhalable formulation of a SARS-CoV-2 neutralizing antibody binding to a conserved epitope on the Spike protein, ensuring pan-neutralizing properties. Administration of this antibody via a vibrating mesh nebulization device retained antibody integrity and resulted in effective distribution of the antibody in the upper and lower respiratory tract of non-human primates (NHP). In comparison with intravenous administration, significantly higher antibody concentrations can be obtained in the lung, resulting in highly effective reduction in viral load post SARS-CoV-2 challenge. This approach may reduce the barriers of access and uptake of antibody therapeutics in real-world clinical settings and provide a more effective blueprint for targeting existing and potentially emerging respiratory tract viruses. COVID-19, caused by the SARS-CoV-2 virus, has had a global impact since the beginning of 2020. Although vaccines were developed and accepted under emergency procedures in under a year–certain populations still remain vulnerable for the viral infection. Monoclonal antibodies could be very potent against viral infections and respiratory diseases, but SARS-CoV-2 has presented many challenges in that field. One being the speed of emerging mutations, which has prevented many developed antibodies from working against later variants, and the other is the route of administration. Here, we developed two monoclonal antibodies of which one lost its virus neutralizing activity due to the mutations in Spike protein. As the second antibody maintained its effectiveness despite the mutational dynamics, we tested it in a viral challenge with non-human primates. We show that nebulization of therapeutic antibody provides significantly higher antibody concentrations in the lungs and airways, where most of the viral replication takes place. Therefore, nebulization could provide a more accessible and effective way of managing respiratory viruses, minimizing potential side effects and cost.

An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies

Bispecific Antibodies Targeting Distinct Regions of the Spike Protein Potently Neutralize SARS-CoV-2 Variants of Concern

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants

Monoclonal Antibodies: Usage in the Treatment of COVID-19 Infection

Editorial: Antiviral monoclonal antibody therapies

Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants

IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2

Neutralizing monoclonal antibodies for treatment of COVID-19

Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection

The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response

Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates

An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects

Emerging anti-spike monoclonal antibodies against SARS-CoV-2

Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19

Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review

A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19)

Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19

Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study